Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: J Hepatol. 2013 Dec 25;60(5):940–947. doi: 10.1016/j.jhep.2013.12.019

Table 4. Matched Cohort study between cirrhotics with and without infection.

Cirrhosis with infection (n=38) Cirrhosis without infection (n=38)
Age (years) 56.0±6.9 58.4±6.8
Gender (Male/Female) 21/17 25/13
Race (Caucasian/African-American/Hispanic/Other) 21/9/5/3 20/13/8/0
Body mass index 29.2±6.7 30.1±6.5
Cirrhosis etiology (HCV, Alcohol, HCV+Alcohol, NASH, others) 11/12/6/6/1 16/9/6/5/2
MELD score 18.2±6.2 18.4±6.8
History of
Variceal Bleeding 5 (13%) 4 (11%)
Hepatic Encephalopathy 28 (73%) 23 (61%)
Medications
Proton pump inhibitors 25 (66%) 24 (63%)
Non-selective beta-blockers 16 (42%) 14 (36%)
Lactulose 15 (40%) 18 (47%)
Rifaximin 17 (45%) 14 (37%)
On SBP prophylaxis 3 (8%) 6 (15%)
Endotoxin (EU/ml) 1.60±1.2 0.65±0.45***
Microbiota (median % abundance Phylum_Taxon)
Phylum Actinobacteria
Actinobacteria_Coriobacteriaceae 0.2 0.5*
Phylum Bacteroidetes
Bacteroidetes_Bacteroidaceae 4.3 21.1
Phylum Firmicutes
Firmicutes_Streptococcaceae 0.0 1.0
Firmicutes_Clostridialies_XIV 0.0 2.4***
Firmicutes_Lachnospiraceae 3.1 14.4***
Firmicutes_Ruminococcaeae 0.7 5.0***
Firmicutes_Veillonellaceae 0.0 1.6***
Phylum Proteobacteria
Protoebacteria_Enterobacteriaceae 1.4 0.0*
Cirrhosis Dysbiosis Ratio 0.34 0.78***

There are no significant differences in the demographics, cirrhosis severity and medication use between the groups. Only microbiota with an abundance ≥1% in any group are shown.

*

p<0.05-0.01,

***

p<0.0001